Tag Archives: ABBV

Hot High Tech Stocks To Buy For 2019

U.S. stock-index futures pointed to a higher open on Wednesday, suggesting the Dow could climb back above the 26,000 level as major indexes looked to trade within striking distance of record levels.

The corporate earnings season continue to be a primary driver of trading, with financial heavyweights in particular view.

What are the main benchmarks doing?

Dow Jones Industrial Average futures
YMH8, +0.52%
were up by 115 points, or 0.5%, to 25,934, while S&P 500 futures
ESH8, +0.40%
added 9.40 points, or 0.3%, to 2,792. Nasdaq-100 futures
NQH8, +0.46%
tacked on 21.50 points, or 0.3%, to 6,783.75.

Hot High Tech Stocks To Buy For 2019: Regal Entertainment Group(RGC)

Advisors’ Opinion:

  • [By Peter Graham]

    In December, UK based Cineworld Group Plc also agreed tobuy larger U.S. peer Regal Entertainment Group (NYSE: RGC) for $3.6 billion in cash in adeal to create the world’s second largest movie theatre operator after AMC Entertainment Holdings. The combined entity is expected to be better able to compete AMC.

Hot High Tech Stocks To Buy For 2019: Brown Forman Corporation(BF.B)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Brown-Forman (BF.B)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot High Tech Stocks To Buy For 2019: AbbVie Inc.(ABBV)

Advisors’ Opinion:

  • [By ]

    Cramer was bearish on Geron (GERN) , Mitek Systems (MITK) , AK Steel Holding (AKS) , Sage Therapeutics (SAGE) and AbbVie (ABBV) .

    Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

  • [By Chris Lange]

    The number of shares short in AbbVie Inc. (NYSE: ABBV) increased to 15.66 million, compared to the previous 15.25 million. The stock was trading at $91.36, in a 52-week range of $64.61 to $125.86.

  • [By ]

    This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV)  , Amgen (AMGN)  , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN)  and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days,” according to Real Money Pro columnist Bret Jensen.

Hot High Tech Stocks To Buy For 2019: Nuveen Premium Income Municipal Fund, Inc.(NPI)

Advisors’ Opinion:

  • [By Logan Wallace]

    Northland Power (TSE:NPI) is set to release its earnings data after the market closes on Wednesday, May 9th. Analysts expect Northland Power to post earnings of C$0.45 per share for the quarter.

Hot High Tech Stocks To Buy For 2019: BioMarin Pharmaceutical Inc.(BMRN)

Advisors’ Opinion:

  • [By ]

    This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV)  , Amgen (AMGN)  , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN)  and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days,” according to Real Money Pro columnist Bret Jensen.

  • [By ]

    In his second “Executive Decision” segment, Cramer sat down with Jean-Jacques Bienaime, chairman and CEO of orphan drugmaker BioMarin Pharmaceuticals Inc.  (BMRN) , to discuss what’s coming down the company’s pipeline.

  • [By Joseph Griffin]

    These are some of the headlines that may have impacted Accern Sentiment’s scoring:

    Get BioMarin Pharmaceutical alerts:

    BioMarin Pharmaceutical (BMRN) Director Sells $318,750.00 in Stock (americanbankingnews.com) BioMarin Pharmaceutical (BMRN) Set to Announce Quarterly Earnings on Wednesday (americanbankingnews.com) BioMarin Pharmaceutical’s (BMRN) “Outperform” Rating Reiterated at BMO Capital Markets (americanbankingnews.com) Three healthcare stocks driving the gene therapy momentum (ca.finance.yahoo.com) 4 Red-Hot Biotech Stocks to Buy Before Earnings (247wallst.com)

    Shares of BioMarin Pharmaceutical stock traded down $1.32 on Friday, hitting $82.30. 2,278,721 shares of the company’s stock traded hands, compared to its average volume of 1,207,934. BioMarin Pharmaceutical has a one year low of $75.81 and a one year high of $100.51. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.70 and a quick ratio of 2.12. The firm has a market cap of $14,490.73, a price-to-earnings ratio of -122.84 and a beta of 1.69.

Hot High Tech Stocks To Buy For 2019: EQT Corporation(EQT)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was EQT Corp. (NYSE: EQT) which rose about 10% to $53.35. The stocks 52-week range is $43.70 to $67.84. Volume was nearly 11 million compared to the daily average volume of 3.6 million.

  • [By ]

    In addition, Elliott Management, which often pushes for M&A and other strategic transactions at targeted companies, made investments in EQT Corp. (EQT) , CommVault Systems Inc. (CVLT) , Sabre Corp. (SABR) , Teradyne Inc. (TER)  and Windstream Holdings Inc. (WIN)

  • [By Max Byerly]

    DekaBank Deutsche Girozentrale raised its stake in shares of EQT (NYSE:EQT) by 85.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 67,281 shares of the oil and gas producer’s stock after purchasing an additional 31,000 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in EQT were worth $3,219,000 at the end of the most recent reporting period.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was EQT Corp. (NYSE: EQT) which traded down over 5% at $49.72. The stocks 52-week range is $43.70 to $67.84. Volume was 7.6 million compared to the daily average volume of nearly 4 million.

Hot Undervalued Stocks To Buy For 2019

Introduction

Several articles appeared in SA noting that Commerzbank AG (OTCPK:CRZBY, the ADR) could be an interesting M&A candidate. We agree with such thesis. The bank is being dramatically undervalued by the market. It is trading at half of its book value per share. In addition, its cash per share is more than ten times its current share price.

Obviously, the political conditions in Europe and the interest rates in the Eurozone are not helping the bank. Additionally, we believe that the EU may not be much interested in seeing mergers between banks. As compared to the US, the financial sector is highly consolidated.

In this article, we will provide all the good and bad reasons for executing a corporate transaction. Furthermore, we will develop several case scenarios. We will also explain how will they affect the share price.

Financial Valuations and Bank Reaction

Before we proceed further, have a look at the most significant financial stats of Commerzbank (source):

Hot Undervalued Stocks To Buy For 2019: AbbVie Inc.(ABBV)

Advisors’ Opinion:

  • [By ]

    Booker’s report took on other companies as well. Pfizer (PFE) , Gilead Sciences (GILD) , AbbVie  (ABBV) , Amgen (AMGN) , Bristol-Myers Squibb (BMY) Eli Lilly & Co. (LLY) , and Mylan NV (MYL) are cited for everything from raising drug prices, to stock buybacks and putting shareholder interest before that of the public.

  • [By Chris Neiger, Anders Bylund, and Todd Campbell]

    To help you track down a few of these companies for your portfolio, we reached out to some Motley Fool contributors for dividend stock ideas. They came back with Uniti Group (NASDAQ:UNIT), AbbVie (NYSE:ABBV), and American Tower (NYSE:AMT). Here’s why.

  • [By Brian Feroldi, Keith Speights, and Sean Williams]

    So which stocks do our healthcare experts have their eye on right now? We asked these three Motley Fool investors to weigh in, and they pickedAbbVie (NYSE:ABBV),Cardinal Health (NYSE:CAH), and Masimo (NASDAQ:MASI).

  • [By George Budwell]

    After releasing downright worrisome first-quarter results, Gilead Sciences (NASDAQ:GILD) has seen its shares drop by a noteworthy 11.7% in the past few days. The big concern is that Gilead’s ailing hepatitis C franchise has yet to stabilize in the wake of newfound competition from AbbVie’s (NYSE:ABBV)Mavyret.

  • [By Keith Speights]

    AbbVie (NYSE:ABBV) ended 2017 with a bang, posting tremendousfourth-quarter results in January. The company has started 2018 with a bang, too.

    On Thursday, AbbVie announced its Q1 earnings results. Wall Street analysts thought the company would report revenue of $7.6 billion. AbbVie’s actual revenue total was $7.9 billion. Analysts expected adjusted earnings per share (EPS) of $1.79. AbbVie reported adjusted EPS in Q1 of $1.87.

  • [By ]

    In keeping with that philosophy, this week’s recommendation for my Income Trader subscribers was in AbbVie (NYSE: ABBV).

    Revisiting This Reliable Trade Target
    I’ve written about AbbVie a few times before. (So far, we’ve made trades on ABBV three times, and all three trades were winners.) It is one of the world’s largest drug makers (the seventh largest by market cap), known to many for its best-selling drug, Humira, a biologic therapy for autoimmune diseases including rheumatoid arthritis, Crohn’s disease and other inflammatory conditions. This is the best-selling drug in the world, with sales of more than $15 billion a year.

Hot Undervalued Stocks To Buy For 2019: ICON plc(ICLR)

Advisors’ Opinion:

  • [By Logan Wallace]

    Senomyx (NASDAQ: SNMX) and ICON (NASDAQ:ICLR) are both consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Hot Undervalued Stocks To Buy For 2019: Aehr Test Systems(AEHR)

Advisors’ Opinion:

  • [By Max Byerly]

    Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:

    Get Aehr Test Systems alerts:

    Critical Comparison: Data I/O (DAIO) & Aehr Test Systems (AEHR) (americanbankingnews.com) Form 4 AEHR TEST SYSTEMS For: May 08 Filed by: HENDRICKSON DAVID S (streetinsider.com) Aehr Test Systems (AEHR) CTO David S. Hendrickson Sells 5,000 Shares (americanbankingnews.com) Teradyne (TER) versus Aehr Test Systems (AEHR) Head to Head Review (americanbankingnews.com) Insider Selling: Aehr Test Systems (AEHR) Insider Sells 20,000 Shares of Stock (americanbankingnews.com)

    AEHR remained flat at $$2.28 during trading hours on Monday. The company had a trading volume of 64,100 shares, compared to its average volume of 136,351. Aehr Test Systems has a 52 week low of $2.26 and a 52 week high of $2.28. The stock has a market cap of $50.06 million, a price-to-earnings ratio of -7.86 and a beta of 0.82. The company has a current ratio of 4.62, a quick ratio of 3.20 and a debt-to-equity ratio of 0.33.

Hot Undervalued Stocks To Buy For 2019: Express Scripts Holding Company(ESRX)

Advisors’ Opinion:

  • [By Cory Renauer]

    Regeneron’s cholesterol-lowering medication Praluent was another drug with multibillion-dollar potential that’s been a huge disappointment in the commercial setting. Trying to launch a treatment with a $14,000-per-year price tag didn’t work, but a more affordable solution is getting attention from the right people. Express Scripts (NASDAQ:ESRX), a pharmacy benefits manager with a national formulary that covers around 25 million Americans, recently agreed to a straightforward reimbursement path in return for drastically lowered pricing. Express Scripts also removed Praluent’s market rival Repatha from its formulary.

  • [By WWW.GURUFOCUS.COM]

    For the details of Jeff Ubben’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Jeff+Ubben

    These are the top 5 holdings of Jeff UbbenTwenty-First Century Fox Inc (FOX) – 53,326,334 shares, 18.41% of the total portfolio. Alliance Data Systems Corp (ADS) – 5,877,400 shares, 15.07% of the total portfolio. CBRE Group Inc (CBG) – 24,916,923 shares, 10.92% of the total portfolio. Shares reduced by 13.72%KKR & Co LP (KKR) – 47,750,000 shares, 10.18% of the total portfolio. Shares added by 4.82%Morgan Stanley (MS) – 17,959,620 shares,

  • [By Cory Renauer]

    Sanofi took the assessment and started engaging end payers to see if any would offer easy reimbursement for a lower net price that reflects ICER’s assessment, and the industry listened. As of July 1, the partners will cut the net price of Praluent in return for straightforward access for around 25 million Americans covered by theExpress Scripts (NASDAQ:ESRX) national formulary. Thepharmacy benefits manager, and will also remove formulary access for its main competitor, Amgen’s (NASDAQ:AMGN) Repatha.

  • [By Alexander Bird]

    Both CVS Health Corp. (NYSE: CVS) and Cigna Corp. (NYSE: CI) sank 5% while Express Scripts Holding Co. (NASDAQ: ESRX), one of the primary providers of pharmacy benefits, dropped 9.7% in response to the disruptive impact the announced partnership could have on the industry. Altogether, the healthcare sector lost a combined $30 billion in market share in the first two hours of trading today.

  • [By Joseph Griffin]

    State of Wisconsin Investment Board boosted its stake in Express Scripts (NASDAQ:ESRX) by 25.1% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 1,092,444 shares of the company’s stock after acquiring an additional 218,855 shares during the quarter. State of Wisconsin Investment Board owned 0.19% of Express Scripts worth $75,466,000 as of its most recent filing with the SEC.

  • [By ]

    Larry Robbins and his Glenview Capital Management LLC said he is supportive of health insurance titan Cigna Corp.’s (CI) acquisition of Express Scripts Holdings Co. (ESRX) , the country’s largest benefits management group, in a deal announced in March worth $67 billion.

Hot Undervalued Stocks To Buy For 2019: New York REIT, Inc.(NYRT)

Advisors’ Opinion:

  • [By Max Byerly]

    New York REIT (NYSE:NYRT) reached a new 52-week high and low on Monday . The stock traded as low as $17.51 and last traded at $17.60, with a volume of 7341 shares traded. The stock had previously closed at $17.85.

Short Sellers Grow More Selective on Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.

The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It has yet to be seen how much headway they can actually make with these reforms.

Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.

The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.

Short interest in Pfizer Inc. (NYSE: PFE) decreased to 81.03 million shares from the previous 98.32 million. The stock was last seen trading at $37.06, within a 52-week range of $31.67 to $39.43.

The number of Merck & Co. Inc. (NYSE: MRK) shares short decreased to 22.95 million from 23.67 million in the previous period. Its shares were trading at $60.09, in a 52-week range of $52.83 to $66.41.

Teva Pharmaceutical Industries Ltd.s (NYSE: TEVA) short interest decreased to 55.84 million from the previous level of 59.40 million. Shares were trading at $17.56, in a 52-week range of $10.85 to $33.82.

Bristol-Myers Squibb Co. (NYSE: BMY) short interest increased to 14.32 million shares from the previous reading of 11.14 million. Shares were trading at $51.58, within a 52-week range of $50.66 to $70.05.

The number of shares short in AbbVie Inc. (NYSE: ABBV) increased to 15.66 million, compared to the previous 15.25 million. The stock was trading at $91.36, in a 52-week range of $64.61 to $125.86.

Eli Lilly and Co.s (NYSE: LLY) short interest decreased to 9.66 million shares from the previous 10.53 million. The stock was trading at $80.09. The 52-week range is $73.69 to $89.09.

ALSO READ: The 6 Most Shorted NYSE Stocks

Top Safest Stocks To Invest In 2018

Today, China is on the verge of something similar to the U.S. in the 1950s…   In 1950, the United States was on the cusp of a boom that would produce the largest middle class in history. It was also the beginning of a surge in the U.S. economy that would make it one of the richest countries ever.   In 2000, just 4% of China's urban population was considered middle class. By 2022, that figure will soar to 76%. That's more than 550 million middle-class people in China.   To put this in perspective, its middle class will be 1.7 times the entire population of the U.S. A growing middle class means Chinese consumer spending will surge, too. It's set to increase 55% between 2015 and 2020.   This means plenty of great opportunities if you're looking for a Chinese stock to buy.   And just like the U.S. did during its boom that started in the middle of the last century, China's middle class is set to spend its money in three key areas…

Top Safest Stocks To Invest In 2018: Beasley Broadcast Group Inc.(BBGI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tuesday afternoon, the cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Beasley Broadcast Group Inc (NASDAQ: BBGI) and Lee Enterprises, Incorporated (NYSE: LEE).

  • [By Benzinga News Desk]

    Beasley Broadcast Group (NASDAQ: BBGI) and Greater Media have entered into a definitive agreement under which Beasley will acquire all of the outstanding stock of Greater Media for approximately $240 million.

Top Safest Stocks To Invest In 2018: Akamai Technologies, Inc.(AKAM)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday was Akamai Technologies, Inc. (NASDAQ: AKAM) which rose about 14% to $65.67. The stocks 52-week range is $44.65 to $71.64. Volume was 14.5 million compared to its average volume of 2 million.

  • [By Anders Bylund]

    Shares of Akamai Technologies (NASDAQ:AKAM) rose 26.7% in 2016, according to data from S&P Global Market Intelligence. Coming off a drastic 28% drop in the last 10 weeks of 2015, the content distribution specialist bounced back quickly.

  • [By Paul Ausick]

    Akamai Technologies Inc. (NASDAQ: AKAM) dropped about 15% Wednesday to post a new 52-week low of $45.45 after closing at $53.28 on Tuesday. The stock’s 52-week high is $71.64. Volume of about 13 million was roughly 5 times the daily average. The company reported decent results, but soft guidance for the current quarter sank the stock in Wednesday’s session.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Akamai Technologies, Inc. (NASDAQ: AKAM) which traded down over 14% at $45.51. The stocks 52-week range is $45.41 to $71.64. Volume wasover 14 million versus the daily average of 2.6 million shares.

Top Safest Stocks To Invest In 2018: Maximus, Inc.(MMS)

Advisors’ Opinion:

  • [By Michael Flannelly]

    Analysts at Jefferies initiated coverage on business process services provider Maximus Inc. (MMS) late on Thursday, giving the stock a bullish rating because it has several competitive advantages and should benefit from the Affordable Care Act (Obamacare).

    The analysts rate MMS as “Buy” and see shares reaching $47. This price target suggests a 20% upside to the stock’s Thursday closing price of $39.14.

    “MMS is a leading government outsourced contractor that produces consistently strong results,” Jefferies analyst David Styblo commented. “The company has several competitive advantages and is highly focused on health and human service projects. This positions MMS to enjoy multi-year growth from the ACA and other opportunities with limited risk. The company’s predictable business model, solid balance sheet, and EPS visibility into FY2014 also support a Buy and $47 PT.”

    Maximus shares were inactive during pre-market trading on Friday. The stock is up 23.83% year-to-date.

  • [By ]

    Maximus Inc (NYSE: MMS) holds just $16 million in long-term debt against $886 million in shareholder equity. Shares trade for 1.7 times sales for a discount of 26% on the industry average of 2.3 times sales.

Top Safest Stocks To Invest In 2018: AbbVie Inc.(ABBV)

Advisors’ Opinion:

  • [By Matt Hogan]

    After applying this technique to the 52 Dividend Aristocrats, there were two companies that stood out: Hormel Foods Corp (NYSE: HRL) and AbbVie Inc (NYSE: ABBV).

  • [By George Budwell]

    Keeping this theme in mind, I think the Dividend Aristocrats AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ), and Medtronic plc (NYSE:MDT) are three outstanding stocks to steady any portfolio during these uncertain times. Here’s why.

  • [By ]

    Spotting This Trend In Real Life
    O’Neil cited a pattern to identify the ideal buy candidate that he called a “cup with handle” pattern. There are precise rules for this charting pattern, but the most important pieces are (1) a pullback (2) followed by a consolidation, like the ones highlighted below in the chart of AbbVie (NYSE: ABBV).

  • [By WWW.GURUFOCUS.COM]

    For the details of MENLO ADVISORS LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=MENLO+ADVISORS+LLC

    These are the top 5 holdings of MENLO ADVISORS LLCBerkshire Hathaway Inc (BRK.B) – 103,443 shares, 15.75% of the total portfolio. Shares reduced by 0.25%Bank of America Corporation (BAC) – 241,490 shares, 5.48% of the total portfolio. Shares reduced by 0.25%Markel Corp (MKL) – 6,158 shares, 5.39% of the total portfolio. Shares reduced by 0.39%AbbVie Inc (ABBV) – 70,185 shares, 5.21% of the total portfolio. Shares reduced by 2.16%Cisco Systems Inc (CSCO) – 165,414 shares, 4.87% o

Top Safest Stocks To Invest In 2018: Female Health Company (The)(FHCO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Female Health Co (NASDAQ: FHCO) were down 15 percent to $1.46 as the company reported that it has entered into a merger agreement with Aspen Park Pharma.

penny stock news

Related SPY First Artificial Intelligence ETF Soars In Popularity On This Day In Market History: Bernie Madoff Arrested CVS And Aetna: The Worst Of Sick-Care Under One Roof (Seeking Alpha)

The SPDR S&P 500 ETF Trust (NYSE: SPY) is up nearly 19 percent in 2017, and much of the rally has been driven by news out of Washington. According to one Wall Street analyst, there are still plenty of political fireworks to come between now and the end of the year.

The Analyst

Height Securities analyst Stefanie Miller.

penny stock news: Alimera Sciences, Inc.(ALIM)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Thursday, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Alimera Sciences Inc (NASDAQ: ALIM) and Anthera Pharmaceuticals Inc (NASDAQ: ANTH).

  • [By Lisa Levin]

    Alimera Sciences Inc (NASDAQ: ALIM) shares shot up 59 percent to $1.69 after the company reported preliminary Q2 revenue. Alimera Sciences announced preliminary revenue of $9.3 million to $9.5 million.

penny stock news: RepliCel Life Sciences Inc. (REPCF)

Advisors’ Opinion:

  • [By Sara Cornell]

    RepliCel Life Sciences Inc. (OTCBB: REPCF) (TSX: RP.V) – could be changing the way we treat baldness and hair loss in the future.

    A clinical-stage regenerative medicine company, RepliCel is developing a unique biologic product that harnesses a patient’s own cells to treat pattern baldness and thinning hair, as well as products for aging and sun-damaged skin, and chronic tendon degeneration. The company recently announced the successful completion of its first-in-human clinical study of autologous cell therapy for the treatment of Androgenetic Alopecia, commonly known as pattern baldness.

penny stock news: SL Green Realty Corporation(SLG)

Advisors’ Opinion:

  • [By Nelson Hem]

    “Manhattan on Sale? That’s the Case With Two Cheap REITS” by Andrew Bary discusses whether Manhattan-focused real estate investment trusts Vornado Realty Trust (NYSE: VNO) and SL Green Realty Corp (NYSE: SLG) could rally as the New York market firms. Both trade at a discount to the value of private-market property deals, says the article.

penny stock news: AbbVie Inc.(ABBV)

Advisors’ Opinion:

  • [By Javier Hasse]

    8:05:11 am: ABBV WYNN Najarian Brothers See Unusual Options Activity In AbbVie And Wynn Resorts. Jon Najarian spoke on CNBC's "Fast Money Halftime Report" about unusually high options activity in AbbVie Inc (NYSE: ABBV). He said that options traders bought aggressively the October 91 calls. He decided to follow the trade and he is planning to hold it…

  • [By Alex McGuire]

    Meanwhile, the 61 healthcare stocks in the S&P 500 – such as AbbVie Inc. (NYSE: ABBV) and Humana Inc. (NYSE: HUM) – offer an average yield of 1.75%.

  • [By Keith Speights]

    I recently bought shares of seven different companies. One of those companies was AbbVie (NYSE:ABBV). I had different reasons for buying each of the stocks. Some were in sectors in which I didn’t already have much exposure in my portfolio. That wasn’t the case with AbbVie, though. I already owned quite a few healthcare stocks and exchange-traded funds (ETFs).